The Registry of Genetic Expression of Taiwan Urologic Cancer

Last updated: May 19, 2025
Sponsor: National Health Research Institutes, Taiwan
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Urologic Cancer

Treatment

N/A

Clinical Study ID

NCT05725304
T1822
  • Ages > 18
  • All Genders

Study Summary

This project is a nationwide precision medicine program for urothelial carcinoma and renal cell carcinoma.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Ages 20 and above. (Age >= 18 years old from January 1, 2023).

  2. Pathological reports showed renal cell carinoma or urothelial carcinoma.

  3. muscle-invasive bladder cancer or positive of N/M grade, UTUC of T2 at least orpositive of N/M grade, or stage III/IV RCC

  4. Willingness to provide the residual biopsy/operative tumor samples for study.

  5. Life expectancy more than 3 months.

  6. Patients fully understand the protocol with the willingness to have regularfollow-up.

Exclusion

Exclusion Criteria:

  1. Inability to cooperate by providing a complete medical history.

  2. Ineligible tumor tissue samples for next-generation sequencing of genetic testing.

  3. Undesirable compliance.

  4. Having a known additional malignancy that is progressing or has required activetreatment within the past 3 years. Participants with basal cell carcinoma of theskin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., cervicalcarcinoma in situ) that have undergone potentially curative therapy are notexcluded.

Study Design

Total Participants: 500
Study Start date:
January 07, 2023
Estimated Completion Date:
October 29, 2029

Study Description

This project providing free and immediate next-generation gene sequencing testing for patients with urothelial and renal cell carcinomas that have is diagnosed or that have previously received systemic therapy. The goal of this project is to assist participating institutions in integrating next-generation sequencing results and building a real-time data storage and sharing platform, as well as establishing a tumor molecular biological atlas of Taiwanese patients with urothelial carcinoma and renal cell carcinoma. The data will be linked with clinical prognosis to facilitate the rapid screening of patients for effective potential therapeutic drugs and clinical trials, which is anticipated to prolong the survival rate of patients.

Connect with a study center

  • Yu wei-lan

    Taipei, 10048
    Taiwan

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.